Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Обоснование выбора антигистаминного препарата для лечения хронической крапивницы и аллергического ринита
Обоснование выбора антигистаминного препарата для лечения хронической крапивницы и аллергического ринита
Смолкин Ю.С. Обоснование выбора антигистаминного препарата для лечения хронической крапивницы и аллергического ринита. Consilium Medicum. 2015; 17 (11): 82–86. DOI:10.26442/2075-1753_2015.11.82-86
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Антигистаминные препараты II поколения являются избирательными антагонистами Н1-рецепторов и препаратами 1-й линии при лечении хронической идиопатической крапивницы и аллергического ринита. В практике аллергологов-иммунологов нередко наблюдаются необоснованность выбора антигистаминного препарата для лечения хронической идиопатической крапивницы и аллергического ринита, а также ничем не оправданные схемы их применения. В статье на примере некоторых известных и авторитетных пострегистрационных исследований, положенных в основу международных согласительных документов и программ – ARIA (Allergic Rhinitis and its Impact on Asthma – Аллергический ринит и его влияние на астму), GA(2)LEN (Global Allergy and Asthma European Network – Глобальная европейская сеть по аллергии и астме), – демонстрируется обоснованность применения одного из антигистаминных препаратов II поколения – дезлоратадина.
Ключевые слова: антигистаминные препараты, хроническая идиопатическая крапивница, аллергический ринит, интермиттирующий аллергический ринит, персистирующий аллергический ринит, дезлоратадин, пострегистрационное наблюдательное исследование.
Ключевые слова: антигистаминные препараты, хроническая идиопатическая крапивница, аллергический ринит, интермиттирующий аллергический ринит, персистирующий аллергический ринит, дезлоратадин, пострегистрационное наблюдательное исследование.
________________________________________________
Antihistamines of II generation are selective H1-receptor antagonists and agents of the 1st-line treatment of chronic idiopathic urticaria and allergic rhinitis. In practice allergist-immunologist is often observed unfounded selecting antihistamine for the treatment of chronic idiopathic urticaria and allergic rhinitis, as well as the unjustified application of the scheme. In the article on the example of some well-known and influential post-marketing studies that formed the basis of international consensus documents and programs – ARIA (Allergic Rhinitis and its Impact on Asthma), GA(2)LEN (Global Allergy and Asthma European Network – a European network of Global allergy and asthma), – demonstrate the validity of the application of one of antihistamines II generation – desloratadine.
Key words: antihistamines, chronic idiopathic urticaria, allergic rhinitis, intermittent allergic rhinitis, persistent allergic rhinitis, desloratadine, post-registration observational study.
Key words: antihistamines, chronic idiopathic urticaria, allergic rhinitis, intermittent allergic rhinitis, persistent allergic rhinitis, desloratadine, post-registration observational study.
Полный текст
Список литературы
1. Victor N, Windeler J, Hasford J et al. Empfehlungen zur Durchführung von Anwendungsbeobachtungen. Informatik Biometrie Epidemiologie Med Biologie 1997; 28: 247–52.
2. Bundesinstitut für Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9. Mai 2007.
3. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticarial in clinical practice: an observational study of 9246 patients. JEADV 2009; 23: 292–9.
4. Greaves MW. Chronicurticaria. N Engl J Med 1995; 332: 1767–72.
5. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316–20.
6. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997; 133: 1003–8.
7. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28: 1101–18.
8. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.
9. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004; 14: 214–20.
10. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR et al. [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.] Rev Alerg Mex 2004; 51: 181–8.
11. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: 196–205.
12. Ozkan M, Ozkan M, Oflaz SB et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99: 29–33.
13. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294–8.
14. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
15. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006; 30: 47–51.
16. Grob JJ, Auquier P, Martin S et al. Development and validation of a quality of life measurement for chronic skin disorders in French: VQ-Dermato. The ReseaudEpidemiolo gie en Dermatologie. Dermatology 1999; 199: 213–22.
17. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60: 1073–8.
18. O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.
19. Patrick DL. Assessing health-related quality of life outcomes. In: Heithoff KA, Lohr KN, editors. Effectiveness and outcomes in health care: proceedings of an invitational conference by the Institute of Medicine. Washington, DC: National Academies Press, 1990; p. 137–51.
20. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
21. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621–3.
22. Grob JJ, Auquier P, Dreyfus I, Ortonne J-P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64: 605–12.
23. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93: 142–6.
24. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289–95.
25. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526–30.
26. Gillard M, Strolin Benedetti M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54: 367–9.
27. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79: 157–62.
28. Holmberg K, Tonnel A-B, Dreyfus I et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64: 1663–70.
29. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407–15.
30. Horak F, Stubner UP, Zieglmayer R et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956–61.
31. Bout J, Ksquehaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
32. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5: 1800–8.
33. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 413–8.
34. Horak F, Stubner UP, Zieglmayer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58: 481–5.
35. Lee DK, Gardiner M, Haggart K et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650–3.
36. Lam HC, Tong MC, van Hasselt CA. Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine. Laryngol Otol 2007; 121: 1151–5.
37. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006; 27: 214–23.
38. Meltzer EO, Jalowayski AA, Vogt K et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006; 96: 363–8.
39. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80.
40. Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838–44.
41. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5): S147–S334.
42. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
43. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005; 60: 350–3.
44. Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35: 728–32.
2. Bundesinstitut für Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9. Mai 2007.
3. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticarial in clinical practice: an observational study of 9246 patients. JEADV 2009; 23: 292–9.
4. Greaves MW. Chronicurticaria. N Engl J Med 1995; 332: 1767–72.
5. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316–20.
6. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997; 133: 1003–8.
7. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28: 1101–18.
8. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.
9. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004; 14: 214–20.
10. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR et al. [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.] Rev Alerg Mex 2004; 51: 181–8.
11. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: 196–205.
12. Ozkan M, Ozkan M, Oflaz SB et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99: 29–33.
13. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294–8.
14. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
15. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006; 30: 47–51.
16. Grob JJ, Auquier P, Martin S et al. Development and validation of a quality of life measurement for chronic skin disorders in French: VQ-Dermato. The ReseaudEpidemiolo gie en Dermatologie. Dermatology 1999; 199: 213–22.
17. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60: 1073–8.
18. O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.
19. Patrick DL. Assessing health-related quality of life outcomes. In: Heithoff KA, Lohr KN, editors. Effectiveness and outcomes in health care: proceedings of an invitational conference by the Institute of Medicine. Washington, DC: National Academies Press, 1990; p. 137–51.
20. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
21. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621–3.
22. Grob JJ, Auquier P, Dreyfus I, Ortonne J-P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64: 605–12.
23. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93: 142–6.
24. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289–95.
25. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526–30.
26. Gillard M, Strolin Benedetti M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54: 367–9.
27. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79: 157–62.
28. Holmberg K, Tonnel A-B, Dreyfus I et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64: 1663–70.
29. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407–15.
30. Horak F, Stubner UP, Zieglmayer R et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956–61.
31. Bout J, Ksquehaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
32. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5: 1800–8.
33. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 413–8.
34. Horak F, Stubner UP, Zieglmayer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58: 481–5.
35. Lee DK, Gardiner M, Haggart K et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650–3.
36. Lam HC, Tong MC, van Hasselt CA. Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine. Laryngol Otol 2007; 121: 1151–5.
37. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006; 27: 214–23.
38. Meltzer EO, Jalowayski AA, Vogt K et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006; 96: 363–8.
39. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80.
40. Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838–44.
41. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5): S147–S334.
42. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
43. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005; 60: 350–3.
44. Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35: 728–32.
2. Bundesinstitut für Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9. Mai 2007.
3. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticarial in clinical practice: an observational study of 9246 patients. JEADV 2009; 23: 292–9.
4. Greaves MW. Chronicurticaria. N Engl J Med 1995; 332: 1767–72.
5. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316–20.
6. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997; 133: 1003–8.
7. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28: 1101–18.
8. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.
9. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004; 14: 214–20.
10. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR et al. [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.] Rev Alerg Mex 2004; 51: 181–8.
11. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: 196–205.
12. Ozkan M, Ozkan M, Oflaz SB et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99: 29–33.
13. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294–8.
14. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
15. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006; 30: 47–51.
16. Grob JJ, Auquier P, Martin S et al. Development and validation of a quality of life measurement for chronic skin disorders in French: VQ-Dermato. The ReseaudEpidemiolo gie en Dermatologie. Dermatology 1999; 199: 213–22.
17. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60: 1073–8.
18. O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.
19. Patrick DL. Assessing health-related quality of life outcomes. In: Heithoff KA, Lohr KN, editors. Effectiveness and outcomes in health care: proceedings of an invitational conference by the Institute of Medicine. Washington, DC: National Academies Press, 1990; p. 137–51.
20. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
21. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621–3.
22. Grob JJ, Auquier P, Dreyfus I, Ortonne J-P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64: 605–12.
23. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93: 142–6.
24. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289–95.
25. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526–30.
26. Gillard M, Strolin Benedetti M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54: 367–9.
27. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79: 157–62.
28. Holmberg K, Tonnel A-B, Dreyfus I et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64: 1663–70.
29. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407–15.
30. Horak F, Stubner UP, Zieglmayer R et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956–61.
31. Bout J, Ksquehaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
32. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5: 1800–8.
33. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 413–8.
34. Horak F, Stubner UP, Zieglmayer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58: 481–5.
35. Lee DK, Gardiner M, Haggart K et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650–3.
36. Lam HC, Tong MC, van Hasselt CA. Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine. Laryngol Otol 2007; 121: 1151–5.
37. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006; 27: 214–23.
38. Meltzer EO, Jalowayski AA, Vogt K et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006; 96: 363–8.
39. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80.
40. Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838–44.
41. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5): S147–S334.
42. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
43. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005; 60: 350–3.
44. Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35: 728–32.
________________________________________________
2. Bundesinstitut für Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9. Mai 2007.
3. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticarial in clinical practice: an observational study of 9246 patients. JEADV 2009; 23: 292–9.
4. Greaves MW. Chronicurticaria. N Engl J Med 1995; 332: 1767–72.
5. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316–20.
6. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol 1997; 133: 1003–8.
7. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28: 1101–18.
8. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.
9. Gaig P, Olona M, Munoz Lejarazu D et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004; 14: 214–20.
10. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR et al. [Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.] Rev Alerg Mex 2004; 51: 181–8.
11. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007; 87: 196–205.
12. Ozkan M, Ozkan M, Oflaz SB et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99: 29–33.
13. Staubach P, Eckhardt-Henn A, Dechene M et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294–8.
14. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
15. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006; 30: 47–51.
16. Grob JJ, Auquier P, Martin S et al. Development and validation of a quality of life measurement for chronic skin disorders in French: VQ-Dermato. The ReseaudEpidemiolo gie en Dermatologie. Dermatology 1999; 199: 213–22.
17. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60: 1073–8.
18. O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197–201.
19. Patrick DL. Assessing health-related quality of life outcomes. In: Heithoff KA, Lohr KN, editors. Effectiveness and outcomes in health care: proceedings of an invitational conference by the Institute of Medicine. Washington, DC: National Academies Press, 1990; p. 137–51.
20. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96–9.
21. Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621–3.
22. Grob JJ, Auquier P, Dreyfus I, Ortonne J-P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64: 605–12.
23. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93: 142–6.
24. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289–95.
25. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526–30.
26. Gillard M, Strolin Benedetti M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005; 54: 367–9.
27. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007; 79: 157–62.
28. Holmberg K, Tonnel A-B, Dreyfus I et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64: 1663–70.
29. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10: 407–15.
30. Horak F, Stubner UP, Zieglmayer R et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956–61.
31. Bout J, Ksquehaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
32. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5: 1800–8.
33. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 413–8.
34. Horak F, Stubner UP, Zieglmayer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58: 481–5.
35. Lee DK, Gardiner M, Haggart K et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650–3.
36. Lam HC, Tong MC, van Hasselt CA. Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine. Laryngol Otol 2007; 121: 1151–5.
37. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006; 27: 214–23.
38. Meltzer EO, Jalowayski AA, Vogt K et al. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006; 96: 363–8.
39. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80.
40. Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838–44.
41. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 5): S147–S334.
42. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
43. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005; 60: 350–3.
44. Bousquet J, Annesi-Maesano I, Carat F et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005; 35: 728–32.
Авторы
Ю.С.Смолкин
ФГБОУ ДПО Институт повышения квалификации ФМБА России. 125371, Россия, Москва, Волоколамское ш., д. 91;
Научно-клинический консультативный центр аллергологии и иммунологии. 117513, Россия, Москва, ул. Островитянова, д. 6
smolking@df.ru
ФГБОУ ДПО Институт повышения квалификации ФМБА России. 125371, Россия, Москва, Волоколамское ш., д. 91;
Научно-клинический консультативный центр аллергологии и иммунологии. 117513, Россия, Москва, ул. Островитянова, д. 6
smolking@df.ru
________________________________________________
Institute of Professional Development. 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91;
Research and Clinical Center of Allergology and Immunology. 117513, Russian Federation, Moscow, ul. Ostrovitianova, d. 6
smolking@df.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.